NCT00660062

Relapse Prevention With Escitalopram or Nortriptyline Following Electro-Convulsive Treatment (DUAG-7)

Relapse Prevention in Patients With a Major Depressive Episode Treated With Electroconvulsive Treatment Using a Fixed Dose Range of Escitalopram Compared to a Fixed Dose of Nortriptyline (DUAG-7) A Randomised Controlled 6 Month Double-blind Study

• Status: Terminated
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 47 (actual)
• Sponsor: Hillerod Hospital, Denmark · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The main purpose of this study is to investigate the relapse preventing efficacy of escitalopram in a dose range and nortriptylin in a single dose in patients having been treated successfully with a course of electroconvulsive treatment (ECT).

Detailed description

This study records severity of depression and relapse in patients treated for a major depressive disorder with electroconvulsive treatment (ECT)in a period og 6 month after end of ECT treatment. Patients will be randomized into four groups treated with escitalopram 10 mg, 20 mg, 30 mg or nortriptylin 100 mg daily dosages. The primary outcome measure is relapse and secondary outcome measure is tolerability. The study is a multicenter trial within Denmark.

Conditions

• Major Depression

Interventions

Type	Name	Description
DRUG	escitalopram	10 mg daily
DRUG	escitalopram	20 mg daily dosage
DRUG	escitalopram	30 mg daily dosage
DRUG	nortriptyline	100 mg daily dosage

Timeline

• Start date: 2009-08-01
• Primary completion: 2014-11-01
• Completion: 2014-11-01
• First posted: 2008-04-17
• Last updated: 2014-12-09

Locations

1 site across 1 country: Denmark